Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Summary.  Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b, with ∼200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized...

Full description

Saved in:
Bibliographic Details
Main Authors: Pianko S., Zeuzem S., Chuang WL., Foster GR., Sarin SK., Flisiak R., Lee CM., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson IM., for the B2202 Study Team.
Format: Article
Language:English
Published: 2014
Online Access:http://www.ncbi.nlm.nih.gov/pubmed/22863266
http://cmuir.cmu.ac.th/handle/6653943832/4001
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English

Similar Items